Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENOLDOPAM MESYLATE vs ALDOCLOR-150
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.
Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.
In-hospital, short-term (up to 48 hours) management of severe hypertension (hypertensive crisis) when rapid, but quickly reversible, blood pressure reduction is required,Off-label: Management of hypertensive emergencies with acute renal impairment
Hypertension
0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.
ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.
Terminal elimination half-life approximately 10 minutes (range 5–20 min) in healthy adults; clinically, continuous infusion is required to maintain therapeutic effect due to rapid clearance.
Terminal elimination half-life is approximately 6-8 hours in patients with normal renal function. In patients with creatinine clearance <30 m L/min, half-life may be prolonged to 15-20 hours, necessitating dose adjustment.
Primarily hepatic via conjugation (glucuronidation and sulfation); CYP450 minimally involved.
Methyldopa is metabolized primarily via conjugation and decarboxylation; chlorothiazide is not extensively metabolized and is excreted unchanged in urine.
Renal (80% as metabolites, 10% as unchanged drug); fecal/biliary minor (10%)
Renal excretion of unchanged drug accounts for approximately 50-60% of the administered dose; hepatic metabolism contributes the remainder, with metabolites excreted via bile and feces. Less than 2% is excreted unchanged in feces.
Approximately 90% bound to plasma proteins, primarily albumin.
Approximately 70-80% bound to plasma proteins, primarily albumin.
0.6–0.8 L/kg; moderate distribution consistent with limited tissue penetration.
Vd is approximately 0.3-0.5 L/kg, indicating distribution primarily in extracellular fluid and limited tissue binding.
Intravenous: 100%; no oral bioavailability due to extensive first-pass metabolism (not administered orally).
Oral bioavailability is approximately 70-80%; food does not significantly alter absorption.
No dose adjustment required for renal impairment; however, monitor for hypotension and electrolyte disturbances.
Contraindicated in patients with GFR <30 m L/min. For GFR 30-50 m L/min, reduce frequency to every other day. For GFR >50 m L/min, no adjustment necessary.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment due to increased risk of hypotension.
Child-Pugh Class A: No adjustment necessary. Child-Pugh Class B: Reduce dose by 50% or extend dosing interval. Child-Pugh Class C: Use is not recommended due to risk of hepatic encephalopathy and fluid retention.
Not FDA-approved for pediatric use; limited data: 0.2 mcg/kg/min IV infusion, titrated to effect; max 0.8 mcg/kg/min.
Not recommended for pediatric use due to lack of safety and efficacy data in patients under 18 years of age.
Start at low end of dosing range (0.1 mcg/kg/min) due to increased sensitivity to hypotension; monitor blood pressure closely.
Initiate at lower dose (e.g., half tablet) due to increased sensitivity to antihypertensive effects, risk of orthostatic hypotension, and impaired renal function. Monitor blood pressure and electrolytes closely.
No FDA black box warning.
None.
Hypotension risk: Monitor blood pressure closely; may cause excessive hypotension.,Tachycardia: Can increase heart rate; caution in patients with coronary ischemia or tachyarrhythmias.,Glaucoma risk: May increase intraocular pressure; avoid in patients with glaucoma.,Hypokalemia: Monitor potassium levels; may cause hypokalemia.
May cause sedation, dizziness, and orthostatic hypotension. Avoid abrupt discontinuation. Use with caution in patients with impaired renal function, liver disease, or history of depression. Monitor for electrolyte imbalance, especially hypokalemia, due to chlorothiazide component.,Methyldopa may cause positive direct Coombs test, hemolytic anemia, and liver disorders. Discontinue if jaundice or liver abnormalities occur.
Known hypersensitivity to fenoldopam or any component,Patients with glaucoma
Hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs.,Active liver disease or previous methyldopa-induced liver disorders.,Anuria or severe renal impairment (creatinine clearance <30 m L/min).
No specific food interactions reported. However, patients should avoid excessive caffeine or stimulants as they may affect blood pressure.
Avoid excessive potassium-rich foods (bananas, oranges, spinach) unless directed, as thiazide can cause potassium loss; however, monitor for hypokalemia. Limit sodium intake to enhance antihypertensive effect. Methyldopa absorption is not significantly affected by food.
Risk in first trimester: No adequate human studies; animal studies show no teratogenic effects at clinically relevant doses. Risk in second and third trimesters: Potential for fetal hypotension and decreased uteroplacental perfusion; use only if clearly needed. Avoid in severe preeclampsia or eclampsia due to risk of significant maternal hypotension.
First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Second and third trimesters: Risk of intrauterine growth restriction (IUGR), oligohydramnios, and renal dysplasia. Neonatal: Folate deficiency, megaloblastic anemia, and potential for methotrexate-like toxicity if used near term.
No data on presence in human milk; M/P ratio unknown. Caution advised; consider benefits of breastfeeding vs potential risk of infant exposure.
Pyrimethamine (component of ALDOCLOR-150) is excreted into breast milk in small amounts; the M/P ratio is not well established. Sulfadoxine (component) is also excreted. Theoretical risk of kernicterus in jaundiced infants due to sulfonamide displacement of bilirubin. Use with caution, especially in preterm or G6PD-deficient infants. The benefits of breastfeeding should outweigh potential risks; alternative antimalarials are preferred.
No standard dose adjustments required; but use lowest effective dose due to increased sensitivity to hypotensive effects in pregnancy. Titrate carefully.
No standard dose adjustment required, but consider increased folic acid supplementation (5 mg daily) to reduce teratogenic risk. Due to increased glomerular filtration rate (GFR) in pregnancy, renal clearance may be enhanced; however, ALDOCLOR-150 is typically used as a single dose and pharmacokinetic data do not support routine dose adjustment. Individualize based on clinical response and toxicity monitoring.
Fenoldopam is a dopamine D1-like receptor agonist used for severe hypertension and hypertensive emergencies. It causes rapid, titratable blood pressure reduction without the toxic metabolites seen with nitroprusside. It also increases renal blood flow and natriuresis, making it beneficial in patients with renal impairment. Avoid in patients with glaucoma (increases intraocular pressure) or sulfite allergy (contains sodium metabisulfite).
ALDOCLOR-150 combines chlorothiazide (a thiazide diuretic) and methyldopa (a central alpha-2 agonist). Monitor for hypokalemia and hyponatremia due to thiazide; methyldopa may cause positive Coombs test (hemolytic anemia risk) and hepatotoxicity. Titrate methyldopa slowly to avoid sedation. Use with caution in renal impairment (Cr Cl <30 m L/min reduces thiazide efficacy).
This medication is given intravenously and is only used in a hospital setting.,You will have your blood pressure and heart rate monitored continuously during the infusion.,Report any headache, flushing, or dizziness to your nurse.,Do not stop the infusion suddenly; the dose will be gradually decreased.,Avoid consuming caffeine or other stimulants during treatment.,Tell your healthcare provider if you have glaucoma or a history of sulfite allergy.
Take medication exactly as prescribed, usually once or twice daily.,May cause dizziness or drowsiness; avoid driving until effects are known.,Stand up slowly to prevent falls from low blood pressure.,Report unexplained fever, fatigue, or jaundice (signs of liver issues).,Avoid alcohol, which enhances sedative effects.,Do not stop abruptly (risk of rebound hypertension).
"Fenoldopam, a dopamine D1-like receptor agonist used for in-hospital blood pressure reduction, can potentiate the hypotensive and hypovolemic effects of the loop diuretic ethacrynic acid. Ethacrynic acid induces sodium and water diuresis, leading to reduced intravascular volume; Fenoldopam causes arterial vasodilation. When co-administered, the combined hemodynamic stress may increase the risk of excessive hypotension, renal hypoperfusion, and acute kidney injury, particularly in patients with compromised cardiac output or volume depletion."
"Iloprost, a prostacyclin analog, enhances vasodilation and inhibits platelet aggregation via IP receptor activation, increasing intracellular cAMP. Fenoldopam, a selective dopamine D1 receptor agonist, induces systemic and renal vasodilation through cAMP-dependent pathways. Concomitant use amplifies the hypotensive effect, potentially leading to severe hypotension, reflex tachycardia, and end-organ hypoperfusion, especially in patients with compromised cardiovascular reserve."
"Amlodipine, a dihydropyridine calcium channel blocker, reduces peripheral vascular resistance by inhibiting calcium influx into vascular smooth muscle cells. Fenoldopam, a selective dopamine D1 receptor agonist, causes arterial vasodilation, particularly in the renal and mesenteric beds. The concurrent use of these two vasodilatory agents leads to additive hypotension, potentially causing symptomatic drops in blood pressure, dizziness, and syncope, especially in patients with pre-existing hypotension or volume depletion."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENOLDOPAM MESYLATE vs ALDOCLOR-150, answered by our medical review team.
FENOLDOPAM MESYLATE is a Antihypertensive that works by Dopamine D1-like receptor agonist (D1 and D5) causing vasodilation in renal, mesenteric, coronary, and cerebral arteries; increases renal blood flow and natriuresis.. ALDOCLOR-150 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-150 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, leading to increased excretion of sodium and water, reducing plasma volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENOLDOPAM MESYLATE and ALDOCLOR-150 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENOLDOPAM MESYLATE is: 0.1 to 0.3 mcg/kg/min IV continuous infusion, titrated every 15-20 minutes by 0.05-0.1 mcg/kg/min; max dose 1.6 mcg/kg/min.. The standard adult dose of ALDOCLOR-150 is: ALDOCLOR-150 is a combination product containing 150 mcg of clonidine and 25 mg of chlorthalidone. The typical adult dose is one tablet orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FENOLDOPAM MESYLATE and ALDOCLOR-150 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FENOLDOPAM MESYLATE is classified as Category C. Risk in first trimester: No adequate human studies; animal studies show no teratogenic effects at clinically relevant doses. Risk in second and third trimesters: Potential for feta. ALDOCLOR-150 is classified as Category C. First trimester: Increased risk of neural tube defects (spina bifida) and other major congenital malformations (e.g., cardiovascular, orofacial clefts) due to folate antagonism. Se. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.